Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of major adverse cardiovascular events, cardiovascular mortality, and heart failure hospitalization in patients with T2DM and established cardiovascular disease or high-risk profiles
Figure 1 summarizes a conceptual overview rather than a single experimental model, developed on the basis of published evidence, with the aim of facilitating the understanding of central and peripheral pathways involved in the GI effects associated with GLP-1 receptor agonists
Metabolic Function : Are your gut bacteria producing beneficial short-chain fatty acids, or are they generating inflammatory compounds
Circulation 148 , 16361664 (2023)
Peripheral neuropathy, subacute combined degeneration of the spinal cord, or cognitive impairment indicate more advanced deficiency and generally require intensive treatment over extended periods
When the fusion rate of macrophages exceeded 90%, the cells were passaged and then subjected to subsequent experiments
